EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY 4.0

Reconsidering Urate-Lowering Therapy in Chronic Kidney Disease- Guideline Driven Perspectives on the Management of Asymptomatic Hyperuricaemia

Sourabh Sharma, Sabine Karam, Intissar Haddiya, Sanjay Kalra

Journal of the Pakistan Medical Association · 28.05.2026 · 76 (06) · 971-974

DOI: 10.47391/jpma.26-46 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Pakistan Medical Association, online erschienen am 28.05.2026. Verfasst von Sourabh Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi. Hauptthemen laut MEDLINE: Hyperuricemia, Renal Insufficiency, Chronic, Gout Suppressants. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperuricaemia is highly prevalent in patients with chronickidney disease (CKD), primarily due to reduced renal urateexcretion. Elevated serum uric acid (SUA) levels have beenlinked with CKD progression, cardiovascular disease, andmortality. However, association does not imply causation.Over the last decade, multiple studies have failed todemonstrate a renoprotective or cardiovascular benefit ofurate-lowering therapy (ULT) in patients withasymptomatic hyperuricaemia. Consequently, majorinternational societies, including Kidney Disease:Improving Global Outcomes (KDIGO), the AmericanCollege of Rheumatology (ACR), and the European Allianceof Associations for Rheumatology (EULAR), recommendagainst pharmacologic treatment of asymptomatichyperuricaemia, including in patients with CKD. This reviewsynthesizes current guideline recommendations,randomized clinical trial evidence, and practical clinicalconsiderations to delineate scenarios in which ULT shouldnot be initiated in patients with chronic kidney disease,while highlighting the importance of supportive and nonpharmacologicmanagement strategies.Keywords: Hyperuricaemia, Chronic kidney disease,Asymptomatic hyperuricaemia, Urate-lowering therapy,Allopurinol, Febuxostat, Gout

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaRenal Insufficiency, ChronicGout SuppressantsHumansPractice Guidelines as TopicFebuxostatAllopurinolUric AcidAsymptomatic Diseases

Stichwörter der Autor:innen

Hyperuricaemia, Chronic kidney disease, Asymptomatic hyperuricaemia, Urate-lowe…

Substanzen

Gout SuppressantsFebuxostatAllopurinolUric Acid

Autor:innen und Institutionen

  • Department of Nephrology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi.
  • Division of Nephrology and Hypertension, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Nephrology, Mohammed VI University Hospital; Faculty of Medicine and Pharmacy of Oujda, Mohammed First University, Oujda, Morocco.
  • Department of Endocrinology, Bharti Hospital, Karnal, India; University Centre for Research & Development, Chandigarh University, Mohali, India.

Zitieren

APA

Sharma, S., Karam, S., Haddiya, I., & Kalra, S. (2026). Reconsidering Urate-Lowering Therapy in Chronic Kidney Disease- Guideline Driven Perspectives on the Management of Asymptomatic Hyperuricaemia. Journal of the Pakistan Medical Association, 76(06), 971-974. https://doi.org/10.47391/jpma.26-46

Vancouver

Sharma S, Karam S, Haddiya I, Kalra S. Reconsidering Urate-Lowering Therapy in Chronic Kidney Disease- Guideline Driven Perspectives on the Management of Asymptomatic Hyperuricaemia. Journal of the Pakistan Medical Association. 2026;76(06):971-974. doi:10.47391/jpma.26-46

BibTeX
@article{Sharma2026,
  author = {Sharma, Sourabh and Karam, Sabine and Haddiya, Intissar and Kalra, Sanjay},
  title = {Reconsidering Urate-Lowering Therapy in Chronic Kidney Disease- Guideline Driven Perspectives on the Management of Asymptomatic Hyperuricaemia},
  journal = {Journal of the Pakistan Medical Association},
  year = {2026},
  volume = {76},
  number = {06},
  pages = {971--974},
  doi = {10.47391/jpma.26-46}
}
Kostenlos starten →